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Abstract
Background: Although it is known that Anderson-Fabry Disease (AFD) can mimic the morphologic manifestations
of hypertrophic cardiomyopathy (HCM) on echocardiography, there is a lack of cardiovascular magnetic resonance
(CMR) literature on this. There is limited information in the published literature on the distribution of myocardial
fibrosis in patients with AFD, with scar reported principally in the basal inferolateral midwall.
Methods: All patients with confirmed AFD undergoing CMR at our center were included. Left ventricular (LV)
volumes, wall thicknesses and scar were analyzed offline. Patients were categorized into 4 groups: 1) no wall
thickening; 2) concentric hypertrophy; 3) asymmetric septal hypertrophy (ASH); and 4) apical hypertrophy. Charts
were reviewed for clinical information.
Results: Thirty-nine patients were included (20 males [51 %], median age 45.2 years [range 22.3–64.4]). Almost half
(17/39) had concentric wall thickening. Almost half (17/39) had pathologic LV scar; three quarters of these (13/17)
had typical inferolateral midwall scar. A quarter (9/39) had both concentric wall thickening and typical inferolateral
scar. A subgroup with ASH and apical hypertrophy (n = 5) had greater maximum wall thickness, total LV scar, apical
scar and mid-ventricular scar than those with concentric hypertrophy (n = 17, p < 0.05). Patients with elevated LVMI
had more overall arrhythmia (p = 0.007) more ventricular arrhythmia (p = 0.007) and sustained ventricular
tachycardia (p = 0.008).
Conclusions: Concentric thickening and inferolateral mid-myocardial scar are the most common manifestations of
AFD, but the spectrum includes cases morphologically identical to apical and ASH subtypes of HCM and these have
more apical and mid-ventricular LV scar. Significant LVH is associated with ventricular arrhythmia.
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Background
X-linked mutations in the α-galactosidase gene cause
Anderson Fabry disease (AFD), a lysosomal storage dis-
order [1]. Although genetic testing is used to diagnose
AFD, cardiovascular magnetic resonance (CMR) is often
performed for accurate volumetric and functional ana-
lysis in this disease and to characterize the myocardium.
It is recognized from the echocardiography literature
that AFD may mimic the morphological characteristics
of the various subtypes of hypertrophic cardiomyopathy.
In addition, a small proportion of AFD patients have no
extracardiac manifestations and therefore, they may be
misdiagnosed as having hypertrophic cardiomyopathy
(HCM) or hypertensive heart disease [2–8]. Although it
is known that AFD can mimic the morphologic manifes-
tations of HCM on echocardiography [5–7, 9–13], CMR
literature on this subject is lacking. There is limited in-
formation in the published literature on the distribution
of myocardial late gadolinium enhancement (LGE) in
patients with AFD, with enhancement reported princi-
pally in the basal inferolateral midwall [14–16]. We
aimed to use the superior myocardial characterization
and spatial resolution of CMR to catalogue the full
spectrum of LGE patterns and distribution of left ven-
tricular wall thickening seen in this rare disease.
Methods
Patient population
Institutional research and ethics board approval was ob-
tained for this retrospective study (REB#: 12-5646-AE)
from the University Health Network Research and Ethics
Board, and the requirement to obtain individual patient
consent was waived. Patients with confirmed AFD, iden-
tified through our metabolic genetic disease clinic be-
tween 1/1/2000 and 31/12/2013, who had CMR (with
LGE sequences) at our institution, were included in this
study. We included only patients with disease-causing
AFD mutation or positive leukocyte alpha galactosidase
A activity test confirming a diagnosis of AFD. Exclusion
criteria were age <18 at CMR acquisition, more than
mild aortic stenosis, disease-causing HCM mutations
and LGE due to myocardial infarction. Arrhythmia was
defined as documented ventricular arrhythmia or atrial
fibrillation. Ventricular arrhythmia was defined as docu-
mented non-sustained ventricular tachycardia (>6 beats
at a minimum of 120 beats/min) and/or an episode (or ep-
isodes) of sustained ventricular tachycardia (ventricular
tachycardia lasting for >30s). Clinical data were abstracted
from the charts by a board-certified cardiologist.
CMR acquisition
CMR was performed on one of the following CMR units:
1.5-T Magnetom Avanto (Siemens Healthcare, Erlangen,
Germany) or Signa HDx Twin Speed (GE Healthcare,
Waukesha, Wisconsin, USA) scanner or a 3.0-T Magne-
tom Verio scanner (Siemens Healthcare). CMR scanners
were equipped with either a 32-element or an eight-
element cardiac array coil. Typical steady-state free pre-
cession parameters were as follows: spatial resolution of
1.3–1.5 x 1.3–1.5 mm, section thickness of 6–10 mm
and gap of 0–2 mm; and temporal resolution of 35–50
msec. LGE was performed with either segmented
gradient-recalled echo or single-shot steady-state free
precession inversion-recovery sequences 8–10 min after
intravenous administration of 0.2 mmol/kg gadobutrol
(Gadovist; Bayer Healthcare, Berlin, Germany).
Image analysis
All studies were reviewed and analyzed by a single expe-
rienced Level III CMR reader using commercially avail-
able CMR post-processing software (cvi42, Calgary,
Canada). The CMR reader was blinded to all clinical
data. Maximum end-diastolic wall thickness (EDWT-
max) was measured manually from cardiac short-axis
(or cardiac long-axis steady state free precession se-
quences for the apical segments where thickened). Wall
thickening was considered to be present if there was an
EDWTmax of >13 mm. The population was divided into
those with and without wall thickening.
Semi-automated (modified centerline technique) aver-
age wall thickness measurements and volumes for each
myocardial segment and LV mass were produced by the
software based on a 16-segment model [17]. Semi-
automated septal to lateral wall ratios (SLR) were ob-
tained by reviewing the average segment wall thicknesses
and dividing the thickest septal segment by the thickest
lateral segment.
We divided the cohort into 4 subgroups based on their
morphological phenotypes; 1) those without wall thicken-
ing; 2) those with apical predominant thickening; 3) those
with asymmetric septal hypertrophy (ASH) (SLR >1.3)
[18] and 4) those with concentric wall thickening
(SLR <1.3).
Left ventricular mass was quantified including LV pap-
illary muscles and trabeculae and was considered ele-
vated when above 85 g/m2 for males and above 81 g/m2
for females when indexed to body surface area (LVMI)
[19]. LV papillary muscle and trabecular mass and vol-
ume were measured and recorded separately [20].
Late gadolinium enhancement (LGE) sequences ac-
quired in conventional cardiac short-axis and 4, 3 and 2-
chamber orientations as well as a stack of LGE images
in a 4-chamber orientation [21] were assessed qualita-
tively for presence and distribution of LV scar. Patients
with LV scar were separated into those with “typical
Fabry scar” (predominantly basal and/or mid inferolat-
eral midwall scar) and those with other patterns of LV
scar. Mild hinge point scar was formally quantified, but
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not considered pathological scar [22]. Semi-automated
threshold-based quantification of LV and segmental scar
was performed by manually adjusting a gray-scale
threshold to define areas of visually-identified LGE [23].
Scar quantification was repeated on a proportion of the
study population to test intraobserver and interobserver
agreement. For intraobserver agreement, scar quantifica-
tion was repeated a minimum of 10 months after initial
analysis.
Statistical analysis
Continuous variables were presented as median (inter-
quartile range). Categorical variables were analyzed with
Fisher’s exact test. Group comparisons were analyzed
using the Mann-Whitney U-test. Spearman correlation
coefficient was utilized to assess correlation between
continuous variables. Intraobserver and interobserver
agreement was assessed by correlation coefficient.
Results
Thirty-nine patients met inclusion criteria (41 patients
with confirmed AFD were identified from clinic data-
base, 1 patient had CMR but no LGE sequences due to
renal impairment and 1 patient was excluded due to an
apical myocardial infarct. Patient characteristics are
given in Table 1). Twenty-two (56 %) had wall thickening
(Fig. 1). Patients with wall thickening were more likely to
be male (68 % vs. 29 %, p = 0.025) and older (49.9 years
[44.9–57.0] vs. 38.9 years [30.7–46.5], p = 0.008). The sep-
tal to lateral wall ratio ranged from 0.76 to 1.61 (median
1.00 [0.92–1.08], Fig. 2). Two (5 %) had an apical predom-
inant pattern of hypertrophy (Figs. 2 and 3), 3 had ASH
morphology (8 %, Fig. 4) and the remainder had concen-
tric wall thickening (n = 17, 44 %, Fig. 5). For statistical
analysis, the asymmetric wall thickening group and apical
thickening group were collapsed into a single ‘non-con-
centric wall thickening’ group (n = 5), Fig. 1. Patients with
non-concentric wall thickening had significantly greater
EDWTmax than those with concentric wall thickening
and there were trends towards greater LVMI (p = 0.066)
(Figs. 3 and 4, Table 2).
LGE analysis
Twenty-five patients (64 %) had evidence of LGE (Fig. 6,
Additional file 1). Eight had predominantly mild hinge
point fibrosis and the remaining 17 had pathological
scar. Of these 17 with pathological scar, 13 (76 %) had a
typical pattern of LGE. Of the 17 with pathological scar,
1 (6 %) had multifocal scar without inferolateral wall
predominance, 2 (12 %) had predominantly apical scar
and 1 (6 %) had mild inferior wall midwall scar. Nine of
17 (53 %) patients with concentric wall thickening had
typical inferolateral scar. Of the 13 patients with typical
inferolateral scar, 8 (62 %) had additional scar elsewhere
in the LV, but not more than in the inferior and lateral
walls. 5 of the 17 (29 %) patients with pathological scar
had scar at the interfaces at fibrous-muscular junctions
(at insertion points of the valve leaflets into the myocar-
dium and at the interface between the chordae tendinae
and papillary muscles). These were better demonstrated
on stacks of 4-chamber orientation LGE images (Fig. 7).
There was moderate correlation between total LV scar
and EDWTmax (rho = 0.52, p = 0.001) as well as
between total LV scar and LVMI (rho = 0.44, p = 0.001.
Patients with non-concentric wall thickening (n = 5) had
more total LV scar, apical LV scar and mid ventricular
Table 1 Clinical characteristics of patients in the cohort
Parameter Result
Age in years (Interquartile range) 45.2 (34.7–55.5)
Males 20 (51 %)
Systemic hypertension 14 (36 %)
New York Heart Association Class I/II 29 (74 %)/10 (26 %)
Atrial fibrillation 5 (13 %)
Ventricular tachycardia 5 (13 %)
Device – Permanent pacemaker/Automated
implantable cardioverter defibrillator
1 (3 %)/3 (8 %)
Enzyme replacement therapy 27 (69 %)
Renal disease
Proteinuria 16 (41 %)
Dialysis/Kidney Transplant 3 (8 %)/3 (8 %)
Other clinical manifestations
Stroke/Transient ischemic attack 12 (31 %)
Auditory manifestations 25 (64 %)
Acroparesthesia 26 (67 %)
Gastrointestinal tract involvement 14 (36 %)
Cutaneous manifestations 18 (46 %)
Fig. 1 Breakdown of AFD cohort according to presence of wall
thickening and the various morphological phenotypes
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LV scar than patients with concentric wall thickening
(n = 17) (Table 2, Fig. 6).
Interobserver agreement was assessed utilizing the 17
cases with pathological scar. Concordance correlation co-
efficient was 0.93 for intraobserver agreement (95 % CI,
0.83 to 0.97) with minimal bias (mean -2.6 g, p = 0.141)
and, 0.98 for interobserver agreement (95 % CI, 0.92 to
0.99) with minimal bias (mean -0.6 g, p = 0.528).
Correlation between imaging and clinical parameters
Twenty-four patients (62 %) had both extracardiac and
cardiac involvement (‘classic variant’); 11 patients (28 %)
Fig. 2 Patterns of left ventricular wall thickening in Anderson-Fabry disease (AFD). Silhouette images of 22 AFD patients with wall thickening
arranged by semi-automated ratios. Cases with the median and lowest and highest values for each ratio are provided to document the full
spectrum of appearances seen in AFD. The septal to lateral wall ratio (a) and the mid inferoseptal to mid anterolateral ratio (b) were chosen to
highlight asymmetric septal hypertrophy and the apical anterior to mid anterior ratio was chosen to highlight preferential apical hypertrophy (c)
Fig. 3 Apical hypertrophy in Anderson-Fabry Disease (AFD). Short-axis (a-c) and 2-chamber (d) cine steady state free precession and short-axis
(e-g) and 2-chamber (h) late gadolinium enhancement images in a patient with Anderson-Fabry Disease on enzyme replacement therapy and a
history of non-sustained ventricular tachycardia. Cardiovascular magnetic resonance revealed an apical pattern of hypertrophy (lack of apical
tapering in end-diastole [white curved arrows on image D]) and obvious intermediate intensity midwall and subendocardial apical scar (white
arrows on images g, h. This is not typical of ischemic heart disease - lack of high intensity myocardial scar and preserved muscle bulk. There is
also subtle intermediate intensity subepicardial scar in the mid inferolateral segment (white arrowheads on image f. There was more scar in the
apical LV than the mid and basal LV (Basal LV scar 10 %; Mid LV scar 9 %; Apical LV scar 38 %)
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Fig. 4 Asymmetric septal hypertrophy in Anderson-Fabry Disease (AFD). Short-axis (a-c) and 4-chamber (d) cine steady state free precession and
short-axis (e-g) and 4-chamber (h) late gadolinium enhancement images in a patient with Anderson-Fabry Disease on enzyme replacement therapy.
The 4 chamber view revealed a reverse septal curvature subtype of asymmetric septal hypertrophy (d). There is a non-ischemic pattern of scar with
high intensity hinge point scar (more so in the anteroseptum than the inferoseptum - dashed arrows on images e-f. There is further intermediate
intensity patchy midwall and subendocardial scar not typical of ischemic heart disease (preserved muscle bulk and patchy sparing of subendocardium
and trabeculae) distributed with an apical predominance (white arrowheads on images G-H). Scar was distributed with an increasing percentage from
base to apex (Basal LV scar 5 %; Mid LV scar 22 %; Apical LV scar 47 %)
Fig. 5 Concentric hypertrophy in Anderson-Fabry Disease (AFD). Short-axis (a-c) and 4-chamber (d) cine steady state free precession and short-axis
(e-g) and 3-chamber (h) late gadolinium enhancement images in a patient with Anderson-Fabry disease who presented who presented initially with
a wide complex tachycardia. Cardiovascular magnetic resonance imaging revealed typical concentric hypertrophy and high intensity inferolateral midwall
scar (dashed white arrows in images e and h. There was also some intermediate intensity mid and apical left ventricular mid-myocardial scar (white
arrowheads in images f-h. There was more scar in the basal LV than the mid and apical LV (Basal LV scar 15 %; Mid LV scar 8 %; Apical LV scar 11 %)
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Table 2 Comparisons between subgroups with concentric wall thickening and non-concentric wall thickening
Concentric wall
thickening (n = 17)
Non-concentric wall
thickening (n = 5)
Statistical significance
(p-value)
Males 12 (71 %) 3 (60 %) 1.000
Age (years) 49.4 (44.1–53.9) 62.2 (51.2–63.8) 0.055
Hypertension 5 (29 %) 4 (80 %) 0.115
EDWTmax (mm) 14.4 (13.3–16.5) 17.3 (16.5–31.0) 0.017
LVEDVI (ml/m2) 83.6 (74.1–108.6) 78.0 (76.4–94.8) 0.845
LVEF (%) 59.3 (56.3–64.6) 57.4 (56.0–66.7) 0.969
LVMI (g/m2) 91.5 (77.2–103.1) 132.7 (93.1–174.7) 0.066
LVPMI (g/m2) 4.8 (3.6–6.4) 5.6 (4.9–9.1) 0.147
LVTPMI ml/m2) 13.8 (10.1–17.0) 20.2 (15.5–22.6) 0.066
Scar as percentage of total LV myocardium (%) 2.8 (1.3–7.0) 14.7 (7.1–21.8) 0.026
Scar as percentage of apical myocardium (%) 0.3 (0.0–1.1) 18.9 (14.4–40.6) 0.003
Scar as percentage of mid-ventricular myocardium (%) 2.0 (1.0–5.2) 9.1 (6.8–21.9) 0.014
Scar as percentage of basal myocardium (%) 4.4 (1.1–8.1) 5.3 (1.4–13.8) 0.411
All data are provided as numbers, percentages or interquartile range where appropriate
EDWTmax Maximum end-diastolic wall thickness, LVMI Indexed left ventricular mass (excluding papillary muscles), LVPMI Indexed left ventricular papillary mass,
LVTPMI Indexed left ventricular trabecular and papillary muscle volume, LVEDVI Indexed left ventricular end-diastolic volume, LVEF Left ventricular ejection fraction
Fig. 6 Scar patterns seen in AFD subdivided according to presence of wall thickening and morphological phenotypes. Visual demonstration of
scar patterns seen in Anderson-Fabry disease subdivided according to presence of wall thickening and morphological phenotypes using color
shading on a 16-myocardial-segment model of the left ventricle. Patients without late gadolinium enhancement were excluded. Numerical
values were assigned to each segment equivalent to the (median) percentage of the segment that was scarred. The population was divided into
subgroups with and without thickening (a-b) and again according to morphological phenotypes comparing concentric (c) and non-concentric (d), ASH
(e), and apical hypertrophy (f) subgroups. ASH = Asymmetric septal hypertrophy. Non-concentric = patients with asymmetric septal hypertrophy +
patients with apical predominant hypertrophy
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had only extracardiac involvement; and 4 patients (10 %)
were carriers. There were no patients in our cohort with
only cardiac manifestations of AFD (‘cardiac variant’).
The majority of ‘classic variant’ patients had wall thick-
ening (92 %), pathological LGE (71 %), typical inferolat-
eral scar (54 %), and concentric wall thickening (71 %).
All patients with non-concentric wall thickening had
‘classic variant’AFD.
There was more arrhythmia in patients with elevated
LVMI (8/16 with elevated LVMI vs. 2/23 with normal
LVMI, p = 0.007). Patients with arrhythmia (n = 10) had
greater LVMI than those without arrhythmia (n = 31),
(111.8 g/m2 [103.0–165.0] vs. 75.9 g/m2 [66.0–89.5],
p = 0.003). Patients with ventricular arrhythmia (n = 5)
had significantly greater LVMI and LV papillary muscle
mass (Table 3). Patients with sustained ventricular tachy-
cardia (n = 2) had greater LVMI, papillary mass and
trabecular and papillary muscle volume (all p = 0.02). Ele-
vated LVMI was associated with ventricular arrhythmia
(4/9 patients with LVMI >125 % of the upper limit of
Fig. 7 Demonstration of scar at fibrous-muscular junctions in Anderson-Fabry disease (AFD). Late gadolinium enhancement images from 2 AFD
patients in our cohort. On the 4-chamber stack and cardiac short-axis late gadolinium enhancement images from a patient on ERT (a-d), high
intensity midwall scar is seen to extend from the aortic annulus into the basal anteroseptal segment (white arrowheads with black border on
image A) and spiral downwards into the basal inferoseptal segment (b-c). Cardiac short-axis image (d) and more inferior slices from the 4-chamber
stack (b-c) demonstrate high intensity scar in the posteromedial papillary muscle group at the junction between the heads and the chordae tendinae
(black arrowheads with white border). On the 4-chamber orientation stack images (e-f) from another patient on enzyme replacement therapy (ERT),
there is a focus of high intensity midwall scar extending from the mitral annulus into the basal inferoseptal segment (white arrowheads with black
border) in this. The 4-chamber orientation stack images (e-f) demonstrate high intensity midwall scar extending from the mitral annulus into the basal
inferoseptal segment (white arrowheads with black border). 3-chamber stack images from the same patient (g-h) demonstrate high intensity midwall
scar extending from the mitral annulus into the basal inferolateral segment (white arrowheads with black border)
Table 3 Comparison between patients with and without ventricular arrhythmia
All ventricular arrhythmia
(n = 5)
No ventricular arrhythmia
(n = 34)
Statistical significance
(p-value)
Total LV mass (g/m2) 132.7 (96.8–193.2) 78.5 (66.1–94.8) 0.029
LV papillary muscle mass (g/m2) 8.6 (5.8–11.0) 4.0 (3.5–5.4) 0.036
Trabecular and papillary muscle volume (ml/m2) 20.2 (12.2–28.1) 11.9 (9.7–16.6) 0.065
Total LV scar (%) 8.9 (0.0–12.3) 1.7 (0.0–4.1) 0.444
Total apical scar (%) 10.6 (0.0–23.8) 0.1 (0.0–0.9) 0.299
Total mid-ventricular scar (%) 8.3 (0.0–8.6) 1.8 (0.0–4.9) 0.495
Total basal scar (%) 1.3 (0.0–11.3) 2.2 (0.0–7.2) 0.966
LV left ventricular
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normal vs. 1/30 with LVMI below this level p = 0.009)
and sustained ventricular tachycardia (2/5 patients with
LVMI >150 % of the upper limit of normal vs. 0/34 with
LVMI below this level p = 0.013,and 2/4 patients with
LVMI >175 % of the upper limit of normal vs. 0/35 with
LVMI below this level p = 0.008) respectively. There
was a significant association between elevated trabecular
and papillary muscle volume and all arrhythmia (p < 0.001),
ventricular arrhythmia (p = 0.010) and sustained
ventricular tachycardia (p = 0.013). There was no sig-
nificant association between LA volume and atrial
fibrillation.
Discussion
Previous CMR literature on AFD has focused on scar
patterns in AFD. Although CMR, with its high spatial
resolution, is ideally suited to assess patterns of LV wall
thickening [24], to our knowledge, this is the first paper
in the CMR literature that has set out to document the
spectrum of wall thickening patterns in AFD and by im-
plication, the potential overlap with HCM with which it
may be confused. The echocardiographic literature on
this subject (summarized in Additional file 2) confirms
that AFD can manifest as ASH and apical hypertrophic
patterns of wall thickening with variable proportions. In
our cohort, we were able to identify subgroups of pa-
tients with concentric wall thickening (19/24, 79 %) and
non-concentric wall thickening (5/24, 21 %). The non-
concentric wall thickening subgroup included patients
with asymmetric septal and apical hypertrophic patterns
and we found that these patients had greater wall thick-
nesses and LVMI than patients with concentric wall
thickening. In one previously reported cohort, over two
thirds of previously undiagnosed AFD patients (ranging
in age between 47 and 79 years) had an ASH pattern of
wall thickening [7], which is at odds with our own co-
hort in whom only one quarter demonstrated asymmet-
ric thickening.
Published CMR findings to date have emphasized the
typical pattern of myocardial scar seen in AFD [14, 16,
25–27] (Additional file 1). However, it was our objective
to obtain a clear picture of the spectrum of disease ex-
pression in this rare condition and we found substantial
variability in scar burden and distribution. We found
that four fifths (79 %) of patients with pathologic LGE
had typical inferolateral scar but that almost two thirds
(60 %) of those with inferolateral scar had other LV scar
as well. Therefore, in our cohort, a fifth (21 %) of patients
with pathological LGE had atypical patterns of scar. Fur-
thermore, patients with non-concentric thickening had
more LV scar and more mid and apical LV scar than those
with concentric thickening. Previous echocardiography-
based research into a small cohort of asymmetric septal
hypertrophy patterns in AFD revealed more short term
adverse events, which was statistically linked to increased
asymmetry and ‘thinning’ of the posterior wall, but there
was no myocardial characterization [7]. We found a
higher percentage of patients (24 %) with atypical scar dis-
tribution than most of the reported cohorts (Additional
file 1), emphasizing the importance of including AFD in
the differential diagnosis of hypertrophic myocardial dis-
ease. Although a recent study has described LGE in myo-
cardial segments outside the typical locations, further
detail or correlation with other imaging or clinical param-
eters was not provided [15]. Our data suggest that patients
with atypical patterns of wall thickening have more total
scar as well as more apical and mid ventricular scar,
whereas most AFD patients have basal inferolateral LGE.
Recent studies have identified non-contrast T1 mapping
as a highly sensitive and specific early marker of cardiac
involvement in AFD [28–30]. At present, however, this se-
quence remains in the research arena and was not utilized
in evaluation of our retrospective cohort. The presence of
LGE remains an important biomarker of disease since it is
one of the indicators that permits funded treatment with
enzyme replacement therapy.
In addition, we found 5 patients with midwall scar at
fibrous-muscular interfaces including valve annuli/LV
wall and chordae tendinae/papillary muscle heads re-
spectively, which to our knowledge has not been de-
scribed in the imaging literature to date. The presence of
papillary scar is unsurprising given the prior reports of
enlarged papillary muscles and disproportionate contri-
bution of trabeculae and papillary muscles to total LV
mass in AFD [15, 31]. We hypothesize these interfaces
between the fibrous skeleton of the heart and the LV
midwall or mesocardial layer are sites of increased stress.
Viewing the mitral annulus as a bucket handle and con-
sidering the basal anteroseptum as the least mobile basal
segment similar to the hinge of the handle, the basal
inferolateral segment (diagonally opposite on the clock
face) is the most mobile of the basal segments and likely
faces the most junctional stresses transmitted from the
fibrous skeleton into the mesocardial layer. Images G-H
from Fig. 7 demonstrate continuity of the scar from the
mitral annulus into the mesocardial layer/midwall of the
basal inferolateral segment. This hypothesis may explain
why midwall basal inferolateral scar is the most common
pattern of myocardial scar in AFD.
Our analysis was limited by the small sample size, but
this is to be expected given of the rarity of the disease,
estimated at between 1 in 7000–8000 live births [32].
For the first time in the literature, our findings have
linked the CMR phenotype to arrhythmia. Intriguingly,
our data raise the possibility of a link between elevated
LV mass and ventricular arrhythmia, as is also seen in
HCM in which significant hypertrophy predicts adverse
events [33]. We found that patients with elevated LV
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mass had more overall arrhythmia and that greater de-
grees of LV hypertrophy, were associated with ventricu-
lar arrhythmia and sustained ventricular tachycardia.
Increased trabecular and papillary muscle volume above
the normal range was associated with overall arrhythmia,
atrial fibrillation, ventricular arrhythmia and sustained
ventricular tachycardia. Given the disproportionate con-
tribution that LV papillary muscle and trabeculations
make to LV mass [15], this finding may be a surrogate
marker for disease severity in Fabry disease rather than
the actual cause of any arrhythmia.
While we found that patients with both ventricular
arrhythmia of any duration had more LV scar, our sample
size was too small to prove a definite association. Lastly,
multivariable logistic regression was not possible due to
the small sample size. As non-concentric patterns of wall
thickening were associated with increased LV mass and
scar, larger multicenter long term outcome studies focus-
ing on AFD patients with these patterns of hypertrophy
and apical predominant scar may be helpful in teasing out
other risk factors for ventricular arrhythmia.
Conclusions
Our cohort demonstrates that Anderson-Fabry disease
has a number of different phenotypic expressions both
in extent and location of hypertrophy and pattern of
scar. There is consequently a direct overlap between the
AFD phenotype and HCM phenotype. It is therefore un-
safe to rely on imaging appearances alone when trying
to exclude or make the diagnosis of AFD, and genetic
testing is still indicated where there is still a reasonable
degree of clinical suspicion. Some centers, including ours,
offer AFD screening to all potential HCM patients be-
cause of the existence of AFD variants with only cardiac
manifestations. Concentric thickening and inferolateral
mid-myocardial scar are the most common manifestations
of AFD, but the spectrum includes cases morphologically
identical to apical and ASH subtypes of HCM and these
have more apical and mid-ventricular LV scar than cases
with concentric thickening. Further research into differ-
ences in clinical outcomes between concentric and non-
concentric morphologic subtypes is warranted in larger
cohorts. Patients with elevated indexed left ventricular
mass in our cohort had a greater incidence of ventricular
arrhythmia. Further research collaborations should focus
on the potential link between LV mass, LV scar burden
and distribution, and ventricular arrhythmia in Anderson
Fabry Disease.
Additional files
Additional file 1: Patterns of late gadolinium enhancement in the
current study population compared to existing literature. (DOC 37 kb)
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